Literature DB >> 28179743

Lixisenatide.

Danial E Baker, Terri L Levien.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The January 2017 monograph topics are bezlotoxumab, buprenorphine buccal, deflazacort, dupilumab, and olaratumab. The DUE is on buprenorphine buccal.

Entities:  

Year:  2017        PMID： 28179743      PMCID： PMC5278917          DOI： 10.1310/hpj5201-65

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  22 in total

1.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Ralph A DeFronzo; Daniel Einhorn; Vivian A Fonseca; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Robert R Henry; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2016-01       Impact factor: 3.443

2.  A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.

Authors:  Justin J Wilkins; Michel Dubar; Bernard Sébastien; Christian Laveille
Journal:  J Clin Pharmacol       Date:  2013-10-19       Impact factor: 3.126

3.  Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).

Authors:  G B Bolli; M Munteanu; S Dotsenko; E Niemoeller; G Boka; Y Wu; M Hanefeld
Journal:  Diabet Med       Date:  2013-10-24       Impact factor: 4.359

4.  Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).

Authors:  M Pinget; R Goldenberg; E Niemoeller; I Muehlen-Bartmer; H Guo; R Aronson
Journal:  Diabetes Obes Metab       Date:  2013-05-26       Impact factor: 6.577

5.  Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.

Authors:  Bernard Charbonnel; Monica Bertolini; Francisco J Tinahones; Manuel Puig Domingo; Melanie Davies
Journal:  J Diabetes Complications       Date:  2014-07-18       Impact factor: 2.852

6.  Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.

Authors:  Michael Nauck; Manfredi Rizzo; Andrew Johnson; Heidrun Bosch-Traberg; Jesper Madsen; Bertrand Cariou
Journal:  Diabetes Care       Date:  2016-06-16       Impact factor: 19.112

7.  Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).

Authors:  Matthew C Riddle; Ronnie Aronson; Philip Home; Michel Marre; Elisabeth Niemoeller; Patrick Miossec; Lin Ping; Jenny Ye; Julio Rosenstock
Journal:  Diabetes Care       Date:  2013-04-29       Impact factor: 19.112

8.  Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.

Authors:  Reinhard H A Becker; Jens Stechl; Axel Steinstraesser; Georg Golor; Franck Pellissier
Journal:  Diabetes Metab Res Rev       Date:  2015-04-23       Impact factor: 4.876

9.  Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia).

Authors:  Y Seino; K W Min; E Niemoeller; A Takami
Journal:  Diabetes Obes Metab       Date:  2012-05-30       Impact factor: 6.577

10.  Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X).

Authors:  Julio Rosenstock; Denis Raccah; László Korányi; Laura Maffei; Gabor Boka; Patrick Miossec; John E Gerich
Journal:  Diabetes Care       Date:  2013-05-22       Impact factor: 19.112
View more
  1 in total

Review 1.  Neuroprotective Mechanisms of Glucagon-Like Peptide-1-Based Therapies in Ischemic Stroke: An Update Based on Preclinical Research.

Authors:  Xiaoyan Yang; Qiang Qiang; Nan Li; Peng Feng; Wenshi Wei; Christian Hölscher
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.